Background & objectives: Although gastric cancer is one of the most common causes of cancer-related death, its prognosis remains poor. Surgical resection with lymph node dissection is the only potentially curative therapy for gastric cancer. However, the appropriate extent of lymph node dissection remains controversial. In East Asian countries, D2 lymph node dissection has been performed as a standard procedure. In western countries, D2 dissection was associated with higher mortality and morbidity with no 5-year survival benefit compared to D1 dissection. More recent studies have demonstrated that western surgeons can be trained to perform D2 lymphadenectomies on achieving survival benefits comparable to those of reported in eastern countries. The aim of our study is to evaluate the feasibility, safety and outcome of extended (D2) lymphadenectomy for gastric cancer. Patients and methods: Between July 2008 and June 2014, patients with gastric cancer in whom surgical resection was indicated, were prospectively included in this study. Enrolled patients underwent gastrectomy with D2 lymphadenectomy. The patients were followed up regularly after the operation. Postoperative parameters, disease-specific mortality & Kaplan- Meier survival analysis were used to assess the outcomes. Results: 62 patients were included in the study. 33 patients had distal gastrectomy and 29 patients had total gastrectomy. 9 (14.5%) patients had postoperative complications with 2 cases of postoperative mortality recorded. The overall mean survival time was 17.13 ±9.6 months and the disease free mean survival time was 13.4 ±9.39 months. Kaplan-Meier survival analysis showed that the overall survival probability estimate in the study was 100% at 1 year, 88.7% at 2 years, 58.1% at 3 years and 32.3% at 4 years. Nodal disease class & N stage were found to have a statistically significant effect on survival. Conclusion: D2 lymphadenectomy can be performed safely in well-equipped hospitals by experienced surgeons with acceptable morbidity & mortality. It can provide better survival for patients with gastric cancer and low degree of lymph node metastases (N1 or N0).